full list rate price target
earn chang report pleas see
tabl page
rais forecast bullish jak
survey call today et
jak inhibitor jak class inflammation/immunolog market
grown dramat late next-gen asset move toward market expect
class continu grow given robust efficaci favor reimburs
patient-friendli oral dose despit safeti concern demand pfizer xeljanz
strong lilly/incyt olumi launch see less robust uptak
new jak approach market upadacitinib approv
gilead/galapago filgotinib file could major valu
driver conduct survey among commun academic/tertiary-
center base rheumatologist evalu current evolv treatment paradigm
commerci prospect jak survey reveal stronger expect
durabl xeljanz suggest continu posit momentum
expect lukewarm review olumi given safeti concern though less
valu driver lilli awar upadacitinib filgotinib commun
set low academic-affili prescrib favor impress
upadacitinib could bode well demand
base survey weve rais forecast near longer term
pfizer xeljanz upadacitinib gilead filgotinib left
lilli olumi unchang result updat rais pt
vs prior pt vs prior remain equal weight
rate stock given growth concern concentr risk worri
maintain gilead pt lilli pt filgotinib
could signific underappreci driver gilead olumi
less focu lilli given growth core diabet franchis earli
product cycl includ emgal verzenio taltz new launch
come pleas join us call slide today et discuss
survey key takeaway despit recent regulatori warn link use xeljanz
remain high patient satisfact efficaci primari reason drive
prescrib cost/access safeti report major barrier
rheumatologist primarili prescrib jak biolog failurepotenti
result contract especi commun set overal low
awar filgotinib upadacitinib respond expect use jak
practic especi earlier within treatment paradigm
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
summari rate price target earn chang report chang shown bold
barclay research share price target price shown primari list currenc ep estim shown report currenc
current fiscal year estim barclay research fiscal year estim barclay research
valuat methodolog risk
valuat methodolog valu use discount cash flow analysi assum wacc impli intrins valu
risk may imped achiev barclay research valuat price biosimilar make greater headway
market cannib share humira could potenti face addit downsid risk humira current compris total
sale declin drug outlook could sever impact earn addit hcv portfolio could fail captur share
exist competit also imbruvica could limit label expans oncolog growth may meet expect pipelin failur
could also drive downsid
valuat methodolog price target base sum-of-the-part approach estim npv valu key
franchis use wacc differ growth rate major product assumpt valu hiv hcv
car-t product pipelin net cash
risk may imped achiev barclay research valuat price commerci risk competit intens
hepat hiv market payor influenc market prefer specif product could neg affect price
could put downward pressur hcv hiv busi would neg impact share perform regulatori
risk gilead broad pipelin produc posit late stage data howev posit data guarante fda ema
grant approv delay timelin inabl gain approv could significantli impact gilead futur sale clinic risk gilead
conduct variou trial virolog oncolog includ car-t diseas earli mid stage agent could fail
demonstr benefit gilead may unabl sustain revenu stream long term patent risk gilead reli patent
protect invest drug develop gilead face multipl patent challeng hcv hiv busi believ gilead
ultim remain market leader virolog neg patent decis event could significantli reduc futur sale pressur
share integr risk car-t categori earli stage market develop gilead may abl success integr
maxim valu acquir asset
valuat methodolog per share price target reflect blend averag discount cash flow analysi impli
intrins valu per share base wacc termin growth rate forward price-to-earnings analysi suggest
modest discount larg cap biopharma averag
risk may imped achiev barclay research valuat price numer grow asset
includ prevnar ibranc xtandi substanti portion innov enbrel viagra lyrica essenti health portfolio face
numer gener competitor price pressur address either intern pipelin success extern acquir asset
result diminish organ growth outlook think use balanc sheet find growth asset howev futur acquisit
may result near-term focu revenu bridg sector consolid rather provid path sustain growth
price target updat vs prior per share price target reflect blend
averag discount cash flow analysi impli intrins valu vs
prior per share base wacc termin growth rate
forward price-to-earnings analysi suggest modest discount larg cap biopharma
million except per share itemspriorcurr chg amort incom attribut common item net -- -- -- nmgaap net ep ep outstand outstand analysispriorcurr chgchg bp gross changepriorcurr chgchg incom incom million except per share itemspriorcurr chg amort incom attribut common item net -- -- -- nmgaap net ep ep outstand outstand analysispriorcurr chgchg bp gross changepriorcurr chgchg incom incom barclay biopharmaceut
price target updat valu use discount cash flow analysi assum
wacc vs prior impli intrins valu vs prior per share
million except per share itemspriorcurrentpriorcurrenthumira non-oper incom ep barclay biopharmaceut
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
larg behind us due settlement
less concern futur
franchis pipelin beyond core
product interest like success
unsur enough make revenu
come introduct humira biosimilar
pipelin success multipl asset indic
would drive revenu thu share price upsid
lessen impact humira biosimilar could also
wors expect impact humira biosimilar
entrant competit prior amgevita
failur pipelin asset could also hamper long-term
overweight exit yz period
new commerci stage portfolio attract diabet
oncolog immunolog asset model
forecast mid single-digit sale low double-digit
ep growth major
pharma averag execut product
cadenc think current multipl
faster expect commerci launch
expect jardianc trulic taltz
baricitinib could drive upsid potenti
multipl expans
slow uptak new diabet immunolog
margin pressur early/intermedi pipelin
failur could caus concern long term
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight gilead move beyond
declin hcv franchis diversifi
oncolog car-t creat intermedi term
visibl could return growth hiv
stabl bictegravir potenti drive
share gain car-t earli stage technolog
hematolog expans solid tumor ad
valu
modest declin hcv robust uptak
taf regimen hiv pipelin success non-
virolog agent larg discount share
would drive upsid de-risk axi-cel addit
hematolog success solid tumor
price pressur drive faster declin hcv
diminish cash flow therebi affect abil
busi develop hiv gener
larger impact expect new taf regimen
experi limit uptak car-t fail expand
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
larg captur upsid key product
prevnar ibranc xtandi absent meaning
busi development/ acquisit see littl
upsid current revenu earn trend
better expect uptak prevnar ibranc
xtandi offset price pressur essenti
coupl pipelin success oncolog
success deploy capit toward could
result upsid forecast
faster eros essenti due price
pressur along lower growth innov could
result weaker top line growth failur deploy
capit pipelin asset could cloud
long-term outlook result share stay
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
